CervoMed Management
Management criteria checks 0/4
CervoMed's CEO is John Alam, appointed in Aug 2023, has a tenure of 2.5 years. total yearly compensation is $1.04M, comprised of 52% salary and 48% bonuses, including company stock and options. directly owns 8.09% of the company’s shares, worth $3.53M. The average tenure of the management team and the board of directors is 1.3 years and 2.5 years respectively.
Key information
John Alam
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 51.96% |
| CEO tenure | 2.5yrs |
| CEO ownership | 8.1% |
| Management average tenure | 1.3yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely
Feb 18
Is CervoMed (NASDAQ:CRVO) In A Good Position To Invest In Growth?
Nov 19CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
Mar 22CervoMed Inc.'s (NASDAQ:CRVO) Price Is Right But Growth Is Lacking
Mar 12CervoMed Inc.'s (NASDAQ:CRVO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Nov 19We're Not Very Worried About CervoMed's (NASDAQ:CRVO) Cash Burn Rate
Aug 24Companies Like CervoMed (NASDAQ:CRVO) Are In A Position To Invest In Growth
Dec 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$26m |
| Jun 30 2025 | n/a | n/a | -US$23m |
| Mar 31 2025 | n/a | n/a | -US$19m |
| Dec 31 2024 | US$1m | US$539k | -US$16m |
| Sep 30 2024 | n/a | n/a | -US$12m |
| Jun 30 2024 | n/a | n/a | -US$5m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$815k | US$472k | -US$2m |
| Sep 30 2023 | n/a | n/a | -US$1m |
| Mar 31 2023 | n/a | n/a | -US$5m |
| Dec 31 2022 | US$594k | US$450k | -US$6m |
Compensation vs Market: John's total compensation ($USD1.04M) is above average for companies of similar size in the US market ($USD577.67K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Alam (63 yo)
Dr. John J. Alam, M.D. serves as Chief Executive Officer at CervoMed Inc. (Formerly, EIP Pharma, LLC) and also serves as its President since August 2023 and serves as its Director since August 2023. He is...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2.5yrs | US$1.04m | 8.09% $ 3.5m | |
| Co-Founder & Director | no data | US$114.95k | 8.09% $ 3.5m | |
| CFO, General Counsel & Corporate Secretary | 5.4yrs | US$651.75k | 0.14% $ 59.0k | |
| Executive Vice President of Technical Operations | less than a year | no data | no data | |
| Executive Vice President of Clinical Development | 7.8yrs | US$465.74k | 0.15% $ 64.5k | |
| Executive VP of Regulatory | 1.3yrs | no data | 0% $ 0 | |
| Senior Vice President of Medical Science | 1.3yrs | no data | no data | |
| Chief Commercial & Business Officer | less than a year | no data | 0.16% $ 70.8k |
Experienced Management: CRVO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2.5yrs | US$1.04m | 8.09% $ 3.5m | |
| Co-Founder & Director | 2.5yrs | US$114.95k | 8.09% $ 3.5m | |
| Independent Chair of the Board | 2yrs | US$228.21k | 11.43% $ 5.0m | |
| Independent Director | 5.5yrs | US$132.92k | 0.0097% $ 4.2k | |
| Member Scientific of Advisory Board | no data | no data | no data | |
| Chair of the Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.5yrs | US$133.92k | 3.82% $ 1.7m | |
| Independent Non-Executive Director | 2.5yrs | US$116.42k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$132.42k | 0.18% $ 77.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | less than a year | no data | no data |
Experienced Board: CRVO's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/17 20:34 |
| End of Day Share Price | 2026/02/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CervoMed Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tyler Bussian | Brookline Capital Markets |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |